TEVA
Teva Pharmaceutical Industries Limited
NYSEUSDEQUITY
Healthcare
DELAYED
Buy
+48/100
Last price
38.99
▼ 0.14 (0.36%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
39.62
Prev close
39.13
Day high
39.39
Day low
38.65
Volume
611.83K
Market cap
$45.47B
P/E (TTM)
64.98
52W range
18.83 – 40.79
Day trading desk
Gap from prior close
+1.25%
Prior close 39.13
VWAP
38.98
+0.03% from price
Relative volume
0.11×
Quiet session
Session range
2.78%
38.55 – 39.62
Position in range
41%
Mid range
ATR (14D)
1.17
3.00% of price
Prior day high
39.93
PDH
Prior day low
38.85
PDL
Bid / ask spread
—
Quote not published
Session volume
605.52K
Avg 5.34M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.54%
-3.0%
1M
+6.07%
+5.0%
3M
+17.79%
+14.8%
6M
+27.75%
+13.2%
YTD
+24.93%
+11.4%
1Y
+95.34%
+80.1%
3Y
+289.51%
+208.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TEVA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-150.98K
Net selling
Buy transactions
3
43.48K shares
Sell transactions
6
194.46K shares
Net transactions
+9
Buys less sells
Sell : buy shares
4.5 : 1
Mixed
Insider-held shares
6.51M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 18, 26 | SAVAGE BRIAN Officer |
SELL | 7.34K | $285.21K | Direct |
| Sep 18, 26 | SAVAGE BRIAN Officer |
CONVERSION | 4.50K | $156.25K | Direct |
| Sep 18, 26 | MIGNONE ROBERTO A. Director |
SELL | 367.60K | $14.36M | Indirect |
| Aug 21, 26 | WEISS AMIR Officer |
SELL | 9.45K | $355.30K | Direct |
| Aug 21, 26 | WEISS AMIR Officer |
CONVERSION | 2.50K | $49.02K | Direct |
| Aug 3, 26 | HUGHES ERIC A Officer |
SELL | 25.58K | $892.05K | Direct |
| Aug 3, 26 | HUGHES ERIC A Officer |
— | 52.74K | — | Direct |
| Aug 3, 26 | JOVER PLACID Officer |
SELL | 12.83K | $447.35K | Direct |
| Aug 3, 26 | JOVER PLACID Officer |
— | 12.83K | — | Direct |
| Jun 11, 26 | KALIF ELIYAHU SHARON Chief Financial Officer |
SELL | 106.56K | $3.63M | Direct |
| Jun 5, 26 | BARER SOL J Director |
— | 21.74K | — | Direct |
| Jun 5, 26 | LIEBERMAN GERALD M Director |
— | 14.49K | — | Direct |
| Jun 5, 26 | CRANE ROSEMARY A Director |
— | 14.49K | — | Direct |
| Jun 5, 26 | FRANCIS RICHARD D Chief Executive Officer |
SELL | 6.15K | $211.36K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BARER SOL J |
Director | 448.01K | Conversion of Exercise of derivative security |
CRANE ROSEMARY A |
Director | 127.74K | Conversion of Exercise of derivative security |
ELSTEIN AMIR |
Director | 2.12M | Conversion of Exercise of derivative security |
FOX CHRISTINE |
Officer | 75.01K | Sale |
FRANCIS RICHARD D |
Chief Executive Officer | 1.18M | Sale |
HUGHES ERIC A |
Officer | 134.88K | Sale |
LIEBERMAN GERALD M |
Director | 130.15K | Conversion of Exercise of derivative security |
MIGNONE ROBERTO A. |
Director | — | Sale |
NISEN PERRY D |
Director | 119.81K | Conversion of Exercise of derivative security |
SABAG MARK |
Officer | 224.94K | Sale |
Fundamentals
Market cap$45.47B
Enterprise value$58.84B
Revenue (TTM)$17.32B
Gross profit$9.08B
EBITDA$4.27B
Net income$706.00M
EPS (TTM)$0.60
Free cash flow$2.22B
Total cash$3.66B
Total debt$16.89B
Book value / share$6.65
Shares outstanding1.17B
Float1.09B
Short % of float2.71%
Dividend yield0.00%
Beta (5Y)0.82
Valuation & profitability ratios
Trailing P/E64.98
Forward P/E12.62
PEG ratio0.71
Price / sales—
Price / book5.86
EV / revenue3.40
EV / EBITDA13.79
Gross margin52.46%
Operating margin4.03%
Profit margin4.08%
Return on equity9.69%
Return on assets5.13%
Debt / equity217.79
Current ratio0.88
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $17.26B | $16.54B | $15.85B | $14.93B | +4.3% |
| Operating revenue | $16.83B | $15.80B | $15.28B | $14.50B | +6.6% |
| Cost of revenue | $8.32B | $8.48B | $8.20B | $7.95B | -1.9% |
| Gross profit | $8.94B | $8.06B | $7.64B | $6.97B | +10.8% |
| Research & development | $1.01B | $998.00M | $953.00M | $838.00M | +1.5% |
| Selling, general & admin | $3.97B | $3.70B | $3.50B | $3.44B | +7.3% |
| Total operating expense | $4.99B | $4.70B | $4.45B | $4.28B | +6.1% |
| Operating income | $3.95B | $3.36B | $3.19B | $2.69B | +17.5% |
| Net interest income | -$985.00M | -$1.05B | -$1.09B | -$991.00M | +6.2% |
| Pre-tax income | $1.22B | -$1.28B | -$624.00M | -$3.16B | +195.2% |
| Tax provision | -$180.00M | $676.00M | -$7.00M | -$643.00M | -126.6% |
| Net income | $1.41B | -$1.64B | -$559.00M | -$2.45B | +186.0% |
| Net income to common | $1.41B | -$1.64B | -$559.00M | -$2.45B | +186.0% |
| Basic EPS | 1.23 | -1.45 | -0.50 | -2.12 | +184.8% |
| Diluted EPS | 1.21 | -1.45 | -0.50 | -2.12 | +183.4% |
| EBIT | $2.14B | -$282.00M | $405.00M | -$2.23B | +858.5% |
| EBITDA | $3.14B | $777.00M | $1.56B | -$925.00M | +304.2% |
| Basic shares | 1.15B | 1.13B | 1.12B | 1.11B | +1.2% |
| Diluted shares | 1.16B | 1.13B | 1.12B | 1.11B | +2.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $3.56B | $3.30B | $3.23B | $2.80B | +7.8% |
| Cash & short-term investments | $3.56B | $3.30B | $3.23B | $2.80B | +7.8% |
| Accounts receivable | $3.71B | $3.06B | $3.41B | $3.70B | +21.2% |
| Inventory | $3.18B | $3.01B | $4.02B | $3.83B | +5.7% |
| Total current assets | $13.95B | $12.55B | $12.48B | $12.05B | +11.1% |
| Property, plant & equipment | $4.42B | $4.95B | $6.15B | $6.16B | -10.6% |
| Goodwill & intangibles | $19.78B | $19.57B | $22.56B | $23.90B | +1.1% |
| Total assets | $40.75B | $39.33B | $43.48B | $44.01B | +3.6% |
| Total current liabilities | $13.46B | $12.80B | $12.25B | $11.47B | +5.2% |
| Current debt | $1.82B | $1.78B | $1.67B | $2.11B | +2.2% |
| Long-term debt | $14.99B | $16.00B | $18.16B | $19.10B | -6.3% |
| Total debt | $17.09B | $18.08B | $20.15B | $21.56B | -5.4% |
| Total liabilities | $32.83B | $33.61B | $35.35B | $35.41B | -2.3% |
| Retained earnings | -$13.76B | -$15.17B | -$13.53B | -$12.97B | +9.3% |
| Shareholder equity | $7.91B | $5.37B | $7.51B | $7.80B | +47.2% |
| Working capital | $490.00M | -$244.00M | $238.00M | $582.00M | +300.8% |
| Net tangible assets | -$11.87B | -$14.19B | -$15.06B | -$16.10B | +16.4% |
| Shares issued | 1.26B | 1.24B | 1.23B | 1.22B | +1.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $1.42B | -$1.96B | -$615.00M | -$2.50B | +172.4% |
| Depreciation & amortisation | $1.00B | $1.06B | $1.15B | $1.31B | -5.4% |
| Stock-based compensation | $157.00M | $123.00M | $121.00M | $124.00M | +27.6% |
| Change in working capital | -$1.37B | -$435.00M | -$72.00M | $1.35B | -214.0% |
| Operating cash flow | $1.65B | $1.25B | $1.37B | $1.59B | +32.2% |
| Capital expenditure | -$501.00M | -$498.00M | -$526.00M | -$548.00M | -0.6% |
| Investing cash flow | $737.00M | $792.00M | $968.00M | $656.00M | -6.9% |
| Financing cash flow | -$2.15B | -$1.79B | -$1.91B | -$1.49B | -20.1% |
| Free cash flow | $1.15B | $749.00M | $842.00M | $1.04B | +53.3% |
| End cash position | $3.56B | $3.30B | $3.23B | $2.83B | +7.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $4.14B | $3.98B | $4.71B | $4.48B | $4.18B | — | +4.0% |
| Operating revenue | $4.07B | $3.82B | $4.60B | $4.36B | $4.06B | — | +6.5% |
| Cost of revenue | $1.99B | $2.01B | $2.06B | $2.18B | $2.07B | — | -1.1% |
| Gross profit | $2.15B | $1.97B | $2.66B | $2.30B | $2.10B | — | +9.2% |
| Research & development | $970.00M | $222.00M | $267.00M | $256.00M | $244.00M | — | +336.9% |
| Selling, general & admin | $1.03B | $1.00B | $1.12B | $973.00M | $959.00M | — | +3.4% |
| Total operating expense | $2.00B | $1.21B | $1.39B | $1.23B | $1.20B | — | +65.2% |
| Operating income | $149.00M | $759.00M | $1.27B | $1.07B | $899.00M | — | -80.4% |
| Net interest income | -$224.00M | -$216.00M | -$271.00M | -$237.00M | -$252.00M | — | -3.7% |
| Pre-tax income | -$455.00M | $437.00M | $80.00M | $646.00M | $203.00M | — | -204.1% |
| Tax provision | $121.00M | $67.00M | -$390.00M | $214.00M | -$78.00M | — | +80.6% |
| Net income | -$576.00M | $369.00M | $480.00M | $433.00M | $282.00M | — | -256.1% |
| Net income to common | -$576.00M | $369.00M | $480.00M | $433.00M | $282.00M | — | -256.1% |
| Basic EPS | -0.49 | 0.32 | 0.42 | — | 0.25 | 0.19 | -253.1% |
| Diluted EPS | -0.49 | 0.31 | 0.41 | — | 0.24 | 0.18 | -258.1% |
| EBIT | -$260.00M | $638.00M | $372.00M | $855.00M | $406.00M | — | -140.8% |
| EBITDA | -$19.00M | $877.00M | $632.00M | $1.10B | $657.00M | — | -102.2% |
| Basic shares | 1.17B | 1.16B | 1.15B | — | 1.15B | 1.16B | +0.8% |
| Diluted shares | 1.17B | 1.18B | 1.17B | — | 1.16B | 1.16B | -1.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.65B | $3.74B | $3.56B | $2.20B | $2.16B | -2.3% |
| Cash & short-term investments | $3.65B | $3.74B | $3.56B | $2.20B | $2.16B | -2.3% |
| Accounts receivable | $3.49B | $3.39B | $3.71B | $3.81B | $3.56B | +2.9% |
| Inventory | $3.22B | $3.18B | $3.18B | $3.32B | $3.50B | +1.4% |
| Total current assets | $13.76B | $13.71B | $13.95B | $12.74B | $12.62B | +0.4% |
| Property, plant & equipment | $4.26B | $4.33B | $4.42B | $5.16B | $5.17B | -1.7% |
| Goodwill & intangibles | $19.29B | $19.43B | $19.78B | $19.88B | $20.09B | -0.7% |
| Total assets | $39.86B | $40.04B | $40.75B | $39.86B | $40.13B | -0.5% |
| Total current liabilities | $15.65B | $13.53B | $13.46B | $11.49B | $11.86B | +15.6% |
| Current debt | $4.50B | $2.61B | $1.82B | $24.00M | $464.00M | +72.3% |
| Long-term debt | $12.09B | $14.02B | $14.99B | $16.77B | $16.76B | -13.7% |
| Total debt | $16.87B | $16.91B | $17.09B | $17.07B | $17.52B | -0.2% |
| Total liabilities | $32.10B | $31.81B | $32.83B | $32.60B | $33.30B | +0.9% |
| Retained earnings | -$13.97B | -$13.39B | -$13.76B | -$14.24B | -$14.68B | -4.3% |
| Shareholder equity | $7.75B | $8.23B | $7.91B | $7.25B | $6.83B | -5.8% |
| Working capital | -$1.89B | $178.00M | $490.00M | $1.25B | $759.00M | -1,159.6% |
| Net tangible assets | -$11.53B | -$11.20B | -$11.87B | -$12.63B | -$13.26B | -2.9% |
| Shares issued | 1.17B | 1.27B | 1.26B | 1.25B | 1.25B | -8.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$575.00M | $369.00M | $481.00M | $434.00M | $283.00M | -255.8% |
| Depreciation & amortisation | $241.00M | $239.00M | $260.00M | $249.00M | $251.00M | +0.8% |
| Stock-based compensation | $40.00M | $43.00M | $51.00M | $34.00M | $38.00M | -7.0% |
| Change in working capital | -$164.00M | -$617.00M | $229.00M | -$561.00M | -$336.00M | +73.4% |
| Operating cash flow | $411.00M | -$40.00M | $1.16B | $369.00M | $227.00M | +1,127.5% |
| Capital expenditure | -$104.00M | -$168.00M | -$142.00M | -$136.00M | -$96.00M | +38.1% |
| Investing cash flow | -$491.00M | $229.00M | $165.00M | $135.00M | $236.00M | -314.4% |
| Financing cash flow | -$1.00M | $13.00M | $40.00M | -$453.00M | $6.00M | -107.7% |
| Free cash flow | $307.00M | -$208.00M | $1.02B | $233.00M | $131.00M | +247.6% |
| End cash position | $3.65B | $3.74B | $3.56B | $2.20B | $2.16B | -2.3% |
Options analytics
Put / call volume
0.18
Call-heavy session
Put / call open interest
1.13
Positioning, not flow
Max pain
40.00
+2.6% from spot
ATM implied vol
42.2%
Nearest strike to spot
Skew (10% OTM)
+9.4%
Puts bid over calls
Call volume
567
Contracts, this expiry
Put volume
101
Contracts, this expiry
Heaviest call OI
40.00
699 contracts
Heaviest put OI
35.00
1.00K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.72 | 6 | $4.24B | -5.4% |
| Next quarter | 0.77 | 6 | $4.23B | -10.3% |
| Current year | 2.15 | 9 | $16.66B | -3.5% |
| Next year | 3.09 | 9 | $17.26B | +3.6% |
Analyst targets & ownership
Mean target$45.30
High target$55.00
Low target$40.00
Implied upside16.18%
Analyst count10
ConsensusBUY
Strong buy / Buy4 / 6
Hold1
Sell / Strong sell0 / 0
Held by insiders0.56%
Held by institutions26.37%
Institutions holding119
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
39.43
-1.12% from price
SMA 20
39.05
-0.16% from price
SMA 50
37.41
+4.22% from price
SMA 100
35.33
+10.37% from price
SMA 200
33.82
+15.30% from price
EMA 12
39.21
-0.56% from price
EMA 26
38.58
+1.06% from price
EMA 50
37.46
+4.09% from price
RSI (14)
53.4
Neutral
MACD (12,26,9)
0.63
Hist -0.15
ATR (14)
1.17
3.00% of price
Realised vol 30D
29.2%
Annualised
Bollinger upper
40.83
20, 2σ
Bollinger lower
37.27
20, 2σ
50 / 200 cross
Golden
37.41 vs 33.82
Trend bias
Above 200
+15.30%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.70
Less volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
29.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-21.8%
Peak to trough
Max drawdown 5Y
-43.7%
Peak to trough
ATR 14
1.17
3.00% of price
Beta (reported)
0.82
5Y monthly, from filing
Short interest
Shares short
31.48M
Latest report
Change vs prior
—
—
% of float
2.71%
Normal
% of shares out
2.70%
Against total outstanding
Days to cover
57.4
Crowded exit
Float
1.09B
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 26 | TD Cowen | INITIATED | — | Buy |
| Sep 23, 26 | Oppenheimer | INITIATED | — | Outperform |
| Sep 9, 26 | Leerink Partners | INITIATED | — | Outperform |
| Sep 4, 26 | UBS | MAINTAINED | Buy | Buy |
| Aug 12, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 28, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| May 6, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Apr 30, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Apr 30, 26 | UBS | MAINTAINED | Buy | Buy |
| Apr 30, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Apr 30, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Apr 9, 26 | B of A Securities | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield1.79%
Payout ratio0.00%
Ex-dividend dateNov 28, 2017
Next pay dateDec 12, 2017
Last split2:1
Split dateJul 1, 2004
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-16
Corporate Changes & Voting Matters
8-K · 2026-09-14
Corporate Changes & Voting Matters
8-K · 2026-09-03
Periodic Financial Reports
10-Q · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-05-28
Periodic Financial Reports
10-Q · 2026-04-29
Proxy Statements
DEF 14A · 2026-03-31
Periodic Financial Reports
10-K · 2026-02-03
Headlines
QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
PR Newswire · 3h ago
What You Need to Know Ahead of Deckers Outdoor’s Earnings Release
Barchart · 2d ago
Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
GlobeNewswire · 5d ago
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
GlobeNewswire · 5d ago
Update: Teva, Samsung Bioepis Partner to Develop, Commercialize Biosimilar Candidates
MT Newswires · 5d ago
Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls
The Fly · 6d ago
Branded Medicines and Pipeline Successes Drive Teva Pharmaceutical Industries’ (TEVA) Margin Expansion
Insider Monkey · 6d ago
Here Are Thursday’s Top Wall Street Analyst Research Calls: BP, Dollar Tree, Exxon Mobil, Lennar, Occidental Petroleum, Rocket Lab, Teva Pharmaceuticals, United Therapeutics, and More
24/7 Wall St. · 6d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.